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Cancer being one of the most dreadful diseases and inflammation in cancer is one of the emerged Hallmarks of cancer. 
Discovering new drugs with minimal side effects plays a vital role in drug development process for the treatment of 
cancer. As an approach antitumor hybrid of “Benzophenone coupled with diamide analog “BT009K” or N-(2-{2-
[4-(4-bromo-benzoyl)-2-methyl-phenoxy]-acetylamino}-phenyl)-2-[2-methyl-4-(2-methyl-benzoyl)-phenoxy] was 
screened against different cell lines. Cytotoxic effect was found to be effective against EAC with prolonged effect. The 
in-vivo antitumor effect was observed in EAC ascites tumor model system with reduced peritoneal neovascularisation. 
Further histological examination with endothelial marker CD31 confirmed the angioregressive effect of BT009K. 
The results were additionally confirmed in a non-tumorigenic model like CAM and rat corneal angiogenesis assay 
indicating reduced microvessel density count by BT009K. Further BT009K induces the anti-invasive effect in EAC 





Cancer is defined as the interplay between cell intrinsic 
and extrinsic process due to the instability in the genome, 
abnormality in the proliferation of cells, inaccuracy in the stromal 
environment and atypical differentiation amongst epithelial 
and mesenchymal status (Eran et al., 2013). The development 
of cancer can be attributed with six vital possessions that cells 
undergo evasion of apoptosis, uncontrolled angiogenesis, 
negligence to anti-proliferative signals, unconstrained replicative 
potential, tissue invasion followed by metastasis (Hanahan and 
Weinberg, 2000). Three phases take place in the development of 
cancer initiation, promotion, and progression. Initiation is started 
through genomic instability in cancer cells promoting for tumor 
development endorsed by the survival and clonal expansion and 
followed by significant growth in tumor size and metastasis of 
tumor cells (Kinzler and Vogelstein, 1996). 
Inflammation, the physiological reaction of the body due 
to the mutilation of tissue damage instigated through microbes, 
wounds, chemical irritation (Philip et al., 2004). Inflammation 
categorized into acute and chronic if the healing of inflammation 
does not take place it progress from acute to chronic inflammation 
resulting in recruitment of lymphocytes, leukocytes and various 
inflammatory cells at the site of the inflamed site. Further chronic 
inflammation mediates to the formation of the tumor by making 
a suitable environment for the cancer cells (Coussens and Werb, 
2002; Nathan, 2002). Inflammation during tumor progression 
induces the angiogenic mediators triggering the angiogenesis 
(Pollard JW, 2006). Angiogenesis is known as restoration and 
progression of the new vascular system from the existing matured 
vasculature to form branching network (Carmeliet, 2005). 
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Extensive angiogenesis plays a major role in tumor formation thus 
chronic inflammation and angiogenesis play synergetic effect in 
cancer. So Blockade of this combination results in the reduction 
of a tumor, in conquest to find a potent inhibitor of inflammatory 
angiogenesis.
Benzophenone molecules bring us hope in this conquest. 
Benzophenone molecules are known for their potency against a 
tumor (Prabhakar et al., 2006) with minimal effect on normal cells. 
As an approach in designing of the compound, we have conjugated 
Diamide to benzophenone and reported “N-(2-{2-[4-(4-bromo-
benzoyl)-2-methyl-phenoxy]-acetylamino}-phenyl)-2-[2-methyl-
4-(2-methyl-benzoyl)-phenoxy] acetamide (BT0009K)” (Fig. 1a) 
has potent antitumor efficacy against multiple cancer cell lines with 
regression of angiogenesis (Zabiulla et al., 2016). In the current 
detailed investigation of BT009K has been carried out to infer that 
it effectively reduces inflammation-induced angiogenesis in both 
tumorigenic and non-tumorigenic model system.
Fig. 1: BT009K acting as potent cytotoxic molecule in in-vitro system, a) Structure of BT009K, b) IC50 value of BT009K against different cell lines, c) Clonogenic 
assay showing the prolonged cytotoxic effect of BT009K in EAC cells in concentration dependent manner, d) Migration assay showing the ability of BT009K in halting 
the migration of EAC cells.
MATERIALS AND METHOD
In-vitro assays
Cell culture and maintenance
Ehrlich Ascites-E (EAC), Dalton’s Ascites Lymphoma 
(DLA), Breast adenocarcinoma (MCF-7), Lung adenocarcinoma 
(A549), Hepatocellular carcinoma (HUH-7, HepG2), human 
melanoma (A375), mouse melanoma (B16F10)cell lines were 
procured from NCCS Pune. Cells were cultured using DMEM or 
RPMI media (Gibco-Invitrogen, USA), with 10% FBS (Invitrogen, 
USA), suitable antibiotics and antimitotic (Sigma Aldrich, USA), 
in a humidified incubator at 37oC with the supply of 5% CO2.
Lactate dehydrogenase assay 
The cytotoxic effect of BT009K was assessed through 
LDH release assay screened against EAC, DLA, Huh-7, Hepg2, 
B16F10, A375, A549, and MCF-7. Cells were treated with or 
without BT009K in different concentration (0, 5, 10, 25, 50, and 
100 µm) for 48 hrs of incubation as stated previously (Ranganath 
et al., 2013). The percentage of LDH released to the media was 
directly proportional to the percentage of dead cells.
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Clonogenic assay
Anti-neoplastic effect of BT009K against EAC cell 
proliferation in-vitro (Franken et al., 2006) was carried out 
accordingly. In brief, EAC cells were cultured in eight-well plate 
in-vitro and exposed with BT009K for 6 hrs and washed with 
fresh medium. After culturing for 12 days 12 days cells were fixed 
with methanol and stained with crystal violet and colonies were 
counted and photographed.
Migration assay
EAC cells were cultured in-vitro, scratched and treated 
with or without BT009K for 48 hrs. Cells were fixed with 
methanol, stained in crystal violet and images were photographed 
at 10X resolution. Differences in the percentage of cell migration 
in treated and control were analyzed (Cory, 2011).
Non tumorigenic assays
Chorioallontoic membrane (CAM) assay
Anti-angiogenic effect of BT009K was analyzed through 
rVEGF165 induced in-vivo CAM assay followed by treatment 
with BT009K within 8 days of fertilized eggs as described earlier 
(Prabhakar et al., 2006). Changes in the microvessel density 
(MVD) count was observed and photographed.
Corneal inflammatory angiogenesis assay
Anti-inflammatory angiogenesis effect of BT009K was 
assessed through rat corneal inflammatory angiogenesis assay by 
anesthetizing the animal with ketamine and xylazine. Followed 
by placing the sterile filter paper discs pre-dipped in 1 M NaOH 
(alkaline solution) and placing it on the eye for 30 seconds. The 
eyes were washed immediately with Phosphate buffer saline for 
inducing inflammatory angiogenesis. The recombinant VEGF165 
was used to enhance the angiogenesis in the cornea in presence or 
absence of BT009K (0, 10, and 20 µm). After 4 days developed 
MVD was observed in the cornea of the rats and quantified. The 
cornea was dissected and processed for histological examination 
for vascular modulation (Prabhu et al., 2017).
Tumorigenic assays
Animal models and ethics
Male Swiss albino mice weighing 25-28 g of 35-45 days 
old were used for this study. Each group consisted of 10 mice caged 
in polyacrylic cages with a supply of standard food and water. 
The Institutional animal ethical committee (IAEC) certificate was 
obtained from SJM College of pharmacy, Chitradurga, India, in 
accordance with the CPCSEA guidelines for laboratory animal 
facility (SJMCP/IAEC/07/2015-16).
Tumor models and treatment
Effect of BT009K in in-vivo tumor model system 
was checked in EAC ascites model system. In brief, Ehrlich 
ascites carcinoma cells (5 × 106 cells) were cultured and 
transplanted into three groups of male Swiss albino mice. Each 
group consists of n = 10 animals. After the development of 
a tumor, BT009K was treated at two different concentration 
50 mg and 75 mg/kg body weight along with appropriate 
vehicle control. Treatment was given on every alternate day 
after tumor establishment. On the last day, (10th day) of tumor 
growth mice was sacrificed and different tumor parameters 
like packed cell volume, ascites volume, tumor growth, and 
survival were assessed (Vijay Avin et al., 2014).
Peritoneal angiogenesis 
The density of Microvessel formation in the peritoneum 
region of a tumor-bearing mice treated with BT009K (50, 75 
mgkg body weight) was assessed as reported earlier (Weidner et 
al., 1991).
Immunohistochemical (IHC) analysis
Peritoneum from the control and BT009K treated mice 
were processed for immunostaining with Anti-CD31 antibody 
for MVD evaluation along with H&E stained counter slides as 
reported earlier (Prabhu et al., 2017). The slides were observed 
in the light microscope and the changes in the intensity of the 
antibody staining were evaluated.
RESULTS AND DISCUSSION 
BT009K induces cytotoxicity against EAC cells
Lactate dehydrogenase (LDH) release assay system is 
one of the gold standard assays to study the cytotoxic ability of 
compound where an increase in the LDH enzyme in the media 
is directly proportional to the number of lysed cells (Chan et al., 
2013). BT009K was screened against EAC, DLA, A549, Huh-7, 
HepG2, MCF-7, A375, and B16F10. Cells were incubated for 
48 hrs with BT009K (0, 5, 10, 25, 50, and 100 µm). BT009K 
(Fig. 1a) showed a significant cytotoxic effect against EAC with 
an IC50 value of 3.9 μm. But moderate activity was reported 
against A549 and MCF-7 and DLA cell lines with 24, 23, and 
23 um, respectively. No significant activity was observed in 
Huh-7, Hepg2, A375, and B16F10 cell lines (Fig. 1b) inferring 
the specificity of BT009K against EAC cells. Each tumor has 
their own drug response and long-term cytotoxicity of drugs 
varies for different tumor cells. Each tumor has individual scale 
against different compounds (Robert, 1991). To check the long-
term ability of BT009K on tumor cells, a clonogenic assay 
was performed which is one of the foremost assay systems to 
evaluate the colony forming ability. The BT009K induces Long-
term cytotoxic effect against EAC cells with the decreased 
number of colonies inferring the prolonged cytotoxic effect 
of the compound on EAC cells in a dose-dependent manner. 
Around 50% decrease in 10 μm concentration and 80% decrease 
in 20 μm concentration as compared to the untreated cells were 
noticed (Fig. 1c). 
Cell migration is one of the fundamental pathological 
and physiological process involved during inflammation, 
cancer and wound healing conditions. During the process of 
cell migration, different proteins and enzymes like VEGF, 
MMP2, 9 play a vital role. Migration of tumor cells is the 
last stage in cancer progression and compound inhibiting 
the migration of tumor cells is vital for regression of a 
tumor, Migration assay is the suitable type of assay to assess 
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the capability of compounds against tumor cell migration 
(Hulkower and Herber 2011). The BT009K regressed the 
migration of tumor cells as observed in migration assay in a 
concentration-dependent manner compared to the control (Fig. 
1d). The result implies BT009K is a potent cytotoxic molecule 
with anti-invasive behavior.
Fig. 2: BT009K reducing micro vessel density in non-tumorigenic models, a) Chorioallontoic membrane assay reduced micro vessel density count in BT009K treated 
compared to the control, b) Rat corneal inflammatory angiogenesis assay showing decreased angiogenesis in the cornea of BT009K treated compared to control, H&E 
staining showing decreased micro vessel density in BT009K treated.
BT009K antiangiogenic molecule in the non-tumorigenic 
model system 
Non-tumorigenic models are often used to check 
the effect of compounds. Chorioallantoic membrane assay 
is one of the supportive angiogenic assay systems were 
rVEGF165 induced neovascularisation is formed (Prabhakar 
et al., 2006). Newly developed vascularisation was reduced 
in BT009K treated egg CAM compared to the untreated in 
a dose-dependent manner (Fig. 2a). Further, the effect of 
BT009K was checked in inflammation-induced angiogenesis 
model viz Rat corneal angiogenesis. In this model, alkali burn 
induces local inflammation in the cornea and which causes 
extensive inflammation of sprouting of a blood vessel (Zhou 
et al., 2010). The BT009K effectively reduces the MVD in 
corneal region induced by inflammation in a concentration-
dependent manner. About ~50% decrease in MVD density in 
10 µm concentration and in 20 µm concentration was nearly to 
the normal (Fig. 2b).
BT009K regresses ascites a tumor in an in-vivo model 
In-vivo ascites tumour model is one of the best model 
systems to study inflammatory mediated angiogenesis were 
tumour cells are cultured in the peritoneum region of mice, 
tumour cells recruit various inflammatory cells and thereby 
inducing angiogenesis by enhancing the pro-angiogenic 
signalling molecules and this results in extensive formation of 
neovascularization and leading to the development of a tumour 
(Vijay Avin et al., 2014). The in-vivo cytotoxic effect of BT009K 
was confirmed by in-vivo culturing EAC cells (5 × 106 cells) in 
the peritoneum region of healthy Swiss albino mice weighing 
about 25-28 g, after the onset of a tumor in mice BT009K was 
treated to mice with two different concentrations, i.e., 50 mg and 
75mg/Kg bwt. Treatment was given for three doses on alternate 
days and resulted in reduced tumor growth in a dose-dependent 
manner compared to the untreated (Fig. 3a). The findings were 
concurrent with other tumor growth parameters like body weight 
(Fig. 3d), ascites secretion (Fig. 3b) and tumor cell counts (Fig. 
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3c). Treatment with BT009K treated also increases with survival 
time than compared with untreated animals (Fig. 3e).
BT009K reduces neovascularisation in peritoneum region 
The ascites tumor model system helps in generating stroma 
when tumor cells are implanted in the peritoneum region thereby 
inducing neovascularization in peritoneum region (Janice et al., 
1995). Neovascularisation during cancer condition benefits a tumor 
by supplying essential nutrients and growth factors for tumor cells, 
endothelial cells express CD31 as cell surface marker during cancer 
condition due to extensive vascularisation expression of CD31 is 
also increased (Weidner et al., 1991). EAC bearing mice are the best 
reliable model to study neovascularisation in the peritoneum region of 
mice. The peritoneum of BT009K treated mice showed reduced MVD 
as seen visibly in the peritoneal lining (Fig. 4a). Further histological 
examination confirmed the reduced MVD count both H&E stain (Fig. 
4b) as well as CD31 immunostain (Fig. 4c).
Fig. 3: In-vivo effect of BT009K in EAC ascites tumour model. a) Physical morphology showing decreased body mass in treated compared to the control. b) Decreased 
ascites volume in treated mice in concentration dependent manner. C) Diminished cell count in BT009K treated mice. d) Reduced tumour growth in BT009K treated 
mice. e) Graph showing prolonged survivality of BT009K treated mice.
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Fig. 4: Peritoneal angiogenesis in ascites tumour model, a) peritoneal angiogenesis induced by EAC cells showing decreased micro vessel density count in BT009K 
treated in concentration dependent manner, b) H&E staining showing decrease in blood vessels in the peritoneum region of BT009K treated mice compared to the 
control mice, c) IHC showing the decreased expression of CD31 in peritoneum of BT009K treated mice.
CONCLUSION 
 Unregulated inflammation turns from acute stage 
to chronic stage leading to malignancy. Inflammation and 
angiogenesis both play a major role in the development of a tumor. 
Benzophenones are known for highly target specific compounds. 
As in the path of development target specific drugs, we focused 
on the coupling of Diamide group to the Benzophenone, which is 
one of the basic approaches to develop an effective drug, BT009K. 
The BT009K was screened against multiple cell lines using LDH 
release assay to evaluate the cytotoxic nature which was found to 
be more effective in EAC with 3.9 μM than any other cell lines 
along with prolonged cytotoxic effect. Down the line, BT009K 
compound implied antiangiogenic effect both in non-tumorigenic 
and this non-tumorigenic model both in-vitro and in-vivo. 
Considering the above results BT009K can be further developed 
as target specific drug in inflammatory angiogenesis disorders.
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